Recent Updates
Recently added Catalysts

quinolone

Phase 3

Bacterial Conjunctivitis | Small molecule | Infectious Disease |Alcon Inc.|Last Updated: Sep 29, 2009

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindUNCONTROLLED
Total Trials1
Total Enrollment600
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00331916AL-15469A for the Treatment of Bacterial ConjunctivitisPHASE3 COMPLETED 600 — — Nov 1, 2005 -Sep 29, 20091 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Clinical cure and microbiological success
Secondary Endpoints
Individual signs and symptoms of bacterial conjunctivitis at each visit
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Interventions
NameTypeDescription
quinoloneDRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range1 Month — N/A
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Signs \& Symptoms of conjunctivitis Exclusion Criteria: * Under 1 mo. age

Countries:United States
Unlock Eligibility Criteria